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1. Introduction 
Viral infections are a significant cause of morbidity and mortality in humans throughout the 
world. However, modern medicine has a very limited ability to prevent viral diseases. 
While traditional vaccination strategies have been highly successful against a subset of 
viruses, the antigenic variation of viruses as well as the shear number of viral pathogens has 
limited the efficacy of this approach.  
This observation is exemplified by the finding that while most common respiratory 
infections are caused by Rhinoviruses, Coronaviruses, Adenoviruses and 
Orthomyxoviruses, a number of other viral families are also frequently implicated. Indeed, 
over 300 serologically distinct viruses are known to cause the pathology associated with the 
‘common cold’ and ‘flu’. [Spector, 1995] Furthermore, vaccinations have yet to prove effective 
against the single viral family (Rhinoviruses) commonly implicated in >60% of common 
colds; again due to the extreme antigenic variability found within even this single viral 
family. As a result, there are currently no broad-spectrum anti-viral prophylactics (either 
prescription or over-the-counter) capable of preventing or interrupting the progression of 
viral infections. 
However, the safe, low cost, low technology, and non-toxic bioengineering of the terminally 
differentiated nasal pharyngeal epithelial host cells may provide a radically new antiviral 
prophylactic approach that gives rise to a transient, broad-spectrum, prophylaxis against 
virally transmitted respiratory infections (Figure 1). [ McCoy & Scott, 2005, Sutton & Scott, 
2010] This polymer-based technology is derivative of the polymer-based 
“immunocamouflage” technology of blood cells being actively developed within the 
Canadian Blood Services to reduce the risk of transfusion reactions and alloimmunization to 
donor red blood cells. [Scott et al., 1997, Scott & Murad, 1998, Murad et al., 1999a, Murad et 
al., 1999b, Bradley et al., 2001, Bradley et al., 2002, Bradley & Scott, 2007, Rossi et al., 2010b]  
As schematically shown in Figure 1, the non-toxic bioengineering of the nasal cavity 
attenuates or prevents viral respiratory infections at the primary site of infection - the 
nasopharyngeal cell surface of the upper respiratory tract. Surprisingly to some, the primary 
mode of viral entry in respiratory diseases is via accidental inoculation of the nasal passage 
via contaminated hands. As demonstrated in Figure 1A, the initial inoculum (1) is typically 
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Fig. 1. Antiviral effects of nasopharyngeal immunocamouflage by activated polymer gel on 
disease pathogenesis. Panel A: Normal viral pathogenesis. Panel B: Effect of mPEG-Nasal 
Gel on viral pathogeniesis. The relative efficacy of the antiviral barrier is denoted by the 
intensity of the blue shading. In Panels A and B, the size of the number relects the relative 
viral number and disease progression: (1) Initial Inoculum; (2) invasion of adjacent cells; (3) 
production of progeny virus; and (4) disease progression to lower respiratory tract. Panel C: 
The antiviral effects of grafted polymer are shown at the epithelial cell membrane-
environment interface. The efficacy of the grafted polymer is shown by the zone of 
protection induced by the small (b), medium (a) and large (c) polymers. RF defines the radius 
of gyration of the grafted polymer. 
small but, upon successful invasion, replicates and produces progeny virus (2) that invade 
adjacent cells (3) producing further progeny that may remain in the upper respiratory tract 
or may progress to the lower respiratory tract (4). [Winther, 2011] However, as shown in 
Figure 1B, the application of the activated mPEG-gel within the nasal cavity covalently 
modifies the terminally differentiated epithelial cells producing a physical and charge 
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neutralization barrier preventing viral recognition of known and unknown viral receptors. 
Consequent to this camouflage, the successful tissue invasion by the initial viral inoculum 
(1) is significantly reduced and few progeny virus (2) are produced. Subsequent replication 
cycles (3) are also reduced decreasing the severity or onset of disease in both the upper and 
lower (4) respiratory tracts. The relative efficacy of the mPEG-antiviral barrier is denoted by 
the intensity of the blue shading and decreases with distance from the nostril opening.  
The antiviral effects of grafted polymer occurs at the epithelial cell membrane-environment 
interface (Figure 1C). The efficacy of the grafted polymer is dependent upon the 
size/topography of the viral receptor and the size (molecular weight; m.w.) of the polymer. 
The size of the polymer governs the Flory radii (RF; root mean square of end to end length of 
the polymer chain; radius of gyration) of the covalently bound polymers and the 
immunocamouflage of viral receptors. This is shown by the zone of protection induced by 
the small (b), medium (a) and large (c) polymers. Note that cell free virus can also be 
modified by the polymer gel resulting in an inability of the PEGylated virus to bind to its 
receptor. The direct PEGylation of the progeny virus further reduces the risk of clinical 
disease.  
In contrast to traditional vaccine approaches, this novel intranasal antiviral prophylactic 
provides immediate, albeit transient, protection against a broad spectrum of respiratory 
viral pathogens. It is these pathogens that can, and do, create massive healthcare 
emergencies in ‘at risk’ populations (displaced individuals, first responders, aid workers 
and healthcare providers) in over-crowded refugee centers and health care facilities 
throughout the world. Indeed, as will be demonstrated, polymer grafting to cells results 
in a global, multivalent, and non-specific inhibition of viral invasion that is practical and 
highly suitable for rapid distribution and easily used by the target populations in a 
variety of environments.  
2. PEGylation: Inhibition of virus-receptor recognition and binding 
Our earlier studies (e.g., erythrocytes, leukocytes and pancreatic islets) demonstrated that 
cells and tissues are readily amenable to the covalent grafting of low immunogenicity 
polymers to the cell membrane or tissue capsule. [Chen & Scott, 2001, Chen & Scott, 2003, 
Chen & Scott, 2006, Murad et al., 1999a, Murad et al., 1999b, Scott & Chen, 2004, Scott et al., 
1997] Successful immunocamouflage of cells, tissues and viruses can be accomplished by a 
number of polymer species such as methoxypoly(ethylene glycol) [mPEG] and 
hyperbranched polyglycerols [HPG]. [Scott et al., 1997, Bradley et al., 2002, Le & Scott, 2010, 
Rossi et al., 2010a, Rossi et al., 2010b] 
Of these polymers, mPEG is the best characterized and is synthesized from poly(ethylene 
glycol) [HO-(CH2CH2O)n-CH2CH2OH]. [Roberts et al., 2002] The first –OH group is used to 
covalently attach the PEG-moiety to a linker compound that in turn is used to covalently 
modify cell membrane proteins. Because the second terminal -OH group of PEG confers 
some residual chemical reactivity, this is replaced by a –CH3 moiety, to form activated 
mPEG: CH3-(CH2CH2O)n-CH2CH2-Linker. Multiple chemical linker groups are currently 
available for the grafting of mPEG to proteins. In general, the majority of these linker agents 
covalently react with lysine residues on membrane surface proteins (Figure 2). Consequent 
to this polymer grafting, our studies have demonstrated that cell charge is camouflaged and 
cell:cell (e.g., Rouleaux formation) and receptor-ligand interactions (e.g., allorecognition and 
antibody binding) are inhibited resulting in immunological camouflage (i.e., 
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immunocamouflage). [Scott et al., 1997, Scott & Murad, 1998, Murad et al., 1999a, Murad et 
al., 1999b, Chen & Scott, 2001, Chen & Scott, 2003, Chen & Scott, 2006, Le & Scott, 2010]  
 
 
Fig. 2. Mechanism of grafting of activated mPEG to cell membrane proteins. Shown is the 
reaction for succinimidyl valerate methoxypoly(ethylene glycol) [SVA-mPEG]. The polymer 
component can be linear (a, b) of variable length (m.w.; a, b denote short and long polymers, 
respectively) or can be highly complex as denoted by the branched (c) structure. The linker 
chemistry is also highly variable but typically targets lysine residues on membrane proteins. 
Lipid anchored PEGs also exist but can negatively impact membrane fluid mechanics 
adversely affecting cell viability. Some work has been done with hyperbranched 
polyglycerols (HPG) which resemble (c). [Le & Scott, 2010, Rossi et al., 2010b]  
Importantly, viral binding to its host cell is highly analogous to receptor-ligand interactions. 
For viral infections to occur, viruses must bind to receptor(s) located on the cell surface 
(Figure 1C). Hence the immunocamouflage of either the virus or host cell would 
theoretically inhibit viral invasion and subsequent disease due to both charge camouflage 
and the steric hindrance resulting from the molecular intra-chain flexibility and rapid 
mobility of the heavily hydrated PEG chains (Figure 3). Moreover, the global camouflage of 
the cell surface effectively masks both known and unknown viral receptors resulting in a 
nonspecific, non-immunological, broad-spectrum antiviral effect. [McCoy & Scott, 2005, 
Sutton & Scott, 2010] 
The biophysical basis of this antiviral effect is schematically shown in Figures 3-4. The PEG 
layer obscures the inherent electrical charge associated with surface proteins since the 
charged molecules become buried beneath the viscous, hydrated, neutral PEG layer. 
[Szleifer, 1997, Satulovsky et al., 2000, Bradley et al., 2002, Bradley & Scott, 2004, Le & Scott, 
2010] As schematically shown in Figure 3, the surface of a generic cell may have a net 
negative charge due to the proteins and carbohydrates present on the cell surface. The 
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Fig. 3. Immunocamouflage of the cell surface is driven by both charge camouflage and steric 
interference induced by the grafted polymer. Surface charge camouflage is primarily driven 
by polymer-mediated extension of the shear plane (SP) of the surface towards a region of 
decreased surface potential (Surface Potential Gradient). In the absence of polymer, the 
inherent shear plane (SP) of a cell is typically located 1-3 nm above the surface. The 
extension of SP is proportional to the hydrodynamic thickness of the polymer layer, which 
in turn is governed by the Flory radii (RF; root mean square of end to end length of the 
polymer chain; radius of gyration) of the covalently bound polymers. Thus, 20 kDa 
polymers (large RF; B) provide improved charge camouflage over 2 kDa polymers (small RF; 
A). Delta (∆) is the difference in the surface potential at the shear plane of a particle 
modified with the short (∆1) vs. the long polymer (∆2). The receptors X, Y and Z denote 
putative viral receptors extending different distances from the cell surface. Modified from 
[Le & Scott, 2010].  
positively charged counter-ions from a bulk aqueous solution migrate and interact with the 
surface to neutralize the surface charge. This creates a Surface Potential Gradient, with the 
electric potential being the highest at the surface and decreasing with the distance away 
from the surface. The Shear Plane (SP) is defined as the region around the surface, where 
counter-ions behave as if they are physically attached to the cell and roughly approximates a 
neutral net charge. Polymer grafting alters the location of the shear plane relative to the 
membrane surface and this change is directly influenced by the size and density of the 
grafted polymer. As demonstrated in Figure 3A, a low molecular weight polymer (e.g., 2 
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kDa) characterized by a small Flory radius (RF approximating the radius of gyration of the 
polymer; 2 kDa mPEG has an RF ~3.5 nm) will move the shear plane away from the surface 
of the cell (∆1). [Heuberger et al., 2005, Damodaran et al., 2010,] However, the grafted 
polymer may or may not camouflage a viral receptor (X, Y, Z) depending on its 
topographical location relative to the SP. In contrast, a high molecular weight polymer (e.g., 
20 kDa; RF = 13.8 nm; Figure 3B) will significantly move the SP away from the membrane 
(∆2) and is more likely to result in the charge camouflage of known and unknown viral 
receptors (X, Y and Z). Moreover, the steric (physical) interference of the grafted polymer 
can also physically prevent the stable interaction of a virus with its surface receptor (Figure 
3). The steric effect is maximized when chains are grafted at higher density; i.e., with a small 
separation between the chains (d). High density grafting is difficult to achieve with 
polymers possessing a large RF (e.g., 20 kDa mPEG; B) as the initially bound chains sterically 
inhibit the approach and binding of additional polymers.  
 
 
Fig. 4. Non-covalent forces mediate receptor-ligand interactions. Partial charges of electric 
dipoles are designated by δ. Electrostatic forces decrease as 1/r2, where r is the distance 
between the two atoms. Van der Waals forces are much weaker than electrostatic forces, 
because the strength of the interaction diminishes as 1/r6. Covalent bonds do not occur 
between a receptor and its ligand. 
The highly malleable nature of mPEG polymers results in a broad range of possibilities of 
enhancing its antiviral effects via the use of both linear or branched molecules over an 
extraordinarily wide range of molecular weights and grafting densities (Figure 2). Of 
biologic importance, the absolute effects arising from both the migration of the SP within the 
Surface Potential Gradient and/or the steric hindrance of viral attachment need only be 
minor as the non-covalent forces that mediate receptor-ligand interactions are relatively 
weak and easily disrupted by the biophysical changes mediated by the grafted polymer 
(Figure 4). Thus, the bioengineering of the nasal pharyngeal epithelial cells with an mPEG 
nasal gel may provide significant opportunities to attenuate or block viral invasion of the 
initial viral inoculum, as well as any progeny, thereby reducing the both disease progression 
and severity. 
A critical concern of this approach is the safety (acute and chronic) of the polymer. PEG is 
generally viewed by the US FDA as a safe compound and is widely used in food, cosmetic 
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and pharmaceutical formulations. Previous studies have demonstrated a lack of toxicity of 
PEG with polymer lengths greater than 400 Da. Human experiments dating from the late 
1940’s demonstrated both orally and intravenously administer PEG (Carbowax®) had no 
acute toxicity. [Shaffer & Critchfield, 1947, Smyth et al., 1947] Indeed, intravenously 
administered PEGs (1 and 6 kDa) were readily excreted by the human kidney. Within 12 
hours, approximately 87.2 ± 2.3% and 96.3 ± 2.4% of the 1 and 6 kDa PEG, respectively, were 
recovered from the urine. More recent (and ethical) studies with PEG-derivatized proteins 
(e.g., PEG-deaminase and PEG-hemoglobin) have also demonstrated that these modified 
compounds (even when of xenobiotic origin) and the PEG itself have few systemic 
consequences and the PEG moiety is similarly excreted via the urine as found in the 1947 
studies. [Veronese & Mero, 2008] PEGylated intact cells have also proven to exert no overt 
toxicity in a murine model. Repeated transfusions of PEGylated erythrocytes in mice have 
demonstrated no adverse events (e.g., no hemolysis, splenomegaly, weight loss) even when 
>80% of their red cell mass was mPEG-RBC. [Murad et al., 1999b] Moreover, there was no 
evidence of anti-PEG antibodies despite the massive infusion of mPEG. Indeed, after two or 
more decades of clinical use of PEGylated proteins, the PEG moiety has proven to be both 
effective in prolonging vascular retention and safe to the recipients of this therapy. 
[Veronese & Harris, 2002, Veronese & Mero, 2008, Veronese & Pasut, 2005] 
3. Broad spectrum antiviral prophylaxis 
Virally mediated respiratory diseases remain a critical problem for humans despite all our 
advances in pharmacology and vaccine development over the last 150 years. [Spector, 1995] 
This is in large part due to the shear number of pathogens (>300 serologically distinct 
viruses) capable of causing the respiratory pathology associated with the ‘common cold’ and 
‘flu’. Many of these viral respiratory diseases are characterized by rapid onset and high 
communicability, especially when introduced into situations characterized by high 
population densities and poor sanitation. Indeed, in refugee centers created following 
natural (e.g., earthquake or flooding) or man-made (e.g., war, bioterrorism or incarceration) 
disasters, epidemic respiratory disease invariably arises within a very short time span and, 
along with diarrhea, is a major cause of morbidity and mortality – especially amongst the 
young and old. Under such emergency conditions, vaccinations (even if immunologically 
plausible) would be of limited utility as there would be insufficient time to adequately 
vaccinate the ‘herd’. Rather, what is needed under these circumstances is an effective 
prophylactic therapy that confers significant individual, thus ‘herd’, protection immediately 
upon application. [Katriel & Stone, 2010, Van Effelterre et al., 2010, Paulke-Korinek et al., 
2011] 
Importantly, for the intervention to be effective, it does not have to inactivate 100% of a viral 
threat. Rather, such prophylactic intervention must reduce the viral exposure to sub-
infective levels and/or inhibit person-to-person transmission. As shown in Figure 5, all 
viruses have a threshold infective level. This may range from 1-2 virions per person for an 
extremely contagious (but not necessarily lethal) virus to several hundred or thousand viral 
particles in order to cause disease. The biologic objective of an activated mPEG-Gel would 
be to reduce the successful invasions of a respiratory virus to a level below the infectious 
dose necessary to cause disease. Moreover, when viewed in the context of ‘herd immunity’ it 
is also not necessary to successfully protect 100% of the at risk population to achieve 
significant protection of the at risk population. As shown in Figure 6, an efficacy of 50% or 
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75% against a theoretical respiratory virus would yield a dramatic reduction in disease 
progression within an at risk population. 
 
 
Fig. 5. The goal of mPEG-modification of either the host cells or virus is not 100% protection 
against viral invasion, but rather reducing the inoculation dose to below the clinically 
infectious dose. For example, in studies of healthy adult humans, a viral dose of 112-448 pfu 
(plaque forming units; a measure of viral load) of Respiratory Syncytial Virus (RSV) Long 
Strain A induced clinical disease in 20 of 41 volunteers. Reduction to less than this critical 
viral load would reduce risk of disease. [Kravetz et al., 1961, Murata & Falsey, 2007]  
With these key concepts in mind, we have been pursuing the functional utility and 
formulation of an anti-viral prophylactic polymer gel against a broad range of viruses in 
vitro (Table 1). Such protection could target either the virus or the potential target as shown 
in Figure 1C. Direct modification of the virus, while highly effective via this technology, is 
not practical for respiratory viruses (in contrast to viruses contained within blood products). 
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Fig. 6. Disease transmission can be dramatically reduced even if the prophylactic nasal gel is 
not 100% effective at the level of the individual (Herd Immunity). As shown, the natural 
progression of a hypothetical respiratory disease is such that 1 infected person transmits 
disease to 4 healthy individuals every 2 days. Diagrammed is the effect that a 50% or 75% 
effective nasal gel would have on an at risk population over 6 days. Previously infected 
individuals are denoted in grey. This model assumes that an individual does not die and 
remains contagious for a minimum of 4 days. 
However, our studies suggest that the application of the activated polymer gel within the 
nasal cavity could prove to be a highly effective antiviral prophylactic (Figure 1B). To 
further explore this prophylactic approach, experimental viruses were chosen to include 
both enveloped and non-enveloped viruses, receptor and fusion mediated viral invasion, 
large and small viruses and to be representative of known human respiratory viruses (e.g., 
Rhinoviruses, Coronaviruses, Adenoviruses).  
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Virus and 
Family 
Virus 
Structure 
Virion 
Size 
Mode of 
Entry 
Receptor 
Receptor 
(nm) 
Mouse 
Adenovirus 
(MAV) 
Adenoviridae 
Naked 
Icosahedral 
Capsid 
70-90 
nm 
Receptor 
Mediated 
Endocytosis
mCAR 4.6 nm 
Rat Coronavirus 
(RCV) 
Coronaviridae 
Enveloped 
Helical 
Capsid 
80-160 
nm 
Fusion 
Not identified - 
other family 
members use 
APN 
13.5nm 
(APN) 
Theiler’s 
Murine 
Encephalo-
myelitis Virus 
(TMEV) 
Picornaviridae 
Naked 
Icosahedral 
Capsid 
28-30 
nm 
Receptor 
Mediated 
Endocytosis
Not identified - 
other family 
members use 
ICAM-1 
18.7 nm 
(ICAM-1) 
Respiratory 
Syncytial Virus 
(RSV) 
Paramyxoviridae 
Enveloped 
Helical 
Capsid 
150-
300 
nm 
Fusion Not Identified Unknown 
Simian Virus 40 
(SV40) 
Papovavirida 
Naked 
Icosahedral 
Capsid 
45-55 
nm 
Receptor 
Mediated 
Endocytosis
MHC-1 7 nm 
Murine Homologue of Coxsackie and Adenovirus Receptor (mCAR); Aminopeptidase N (APN); 
Intracellular Adhesion Molecule-1 (ICAM-1); and Major Histocompatibility Molecule-1 (MHC-1). SV40 
is not a respiratory virus but is a well characterized experimental model suitable for experimental 
study. Receptor size references as follows: MHC-1 [Bjorkman et al., 1987]; mCAR [He et al., 2001]; APN 
[Hussain et al., 1981]; EGFR [Mi et al., 2008]; ICAM-1 [Jun et al., 2001] 
Table 1. Partial Listing of Experimental Viral Models Utilized in the Evaluation of the 
Proposed Antiviral Prophylactic Nasal Gel. 
3.1 Antiviral nasal gel 
To determine if an activated mPEG-gel could inhibit viral invasion and proliferation, in vitro 
studies were conducted using the viruses described in Table 1. These studies examined both 
direct polymer modification of the viruses themselves as well as their host (target) cells.  
To determine if viruses were amenable to PEGylation by the chemistry noted in Figure 2, an 
analysis of envelope and capsid proteins was done. The amino acid composition and 
sequence of the envelope and capsid proteins suggested that all viruses had suitable targets 
for lysine based grafting. For example, analysis of a number of human RSV isolates 
demonstrate that both the F and G capsid glycoproteins are lysine rich and provide an 
excellent substrate for direct viral modification with mPEG. Infection assays confirmed this 
analysis. These experiments demonstrated that direct covalent modification of the virion by 
mPEG resulted in an almost complete abrogation of viral infection and proliferation [Sutton 
& Scott, 2010]. However some significant variability in the efficacy of small and large 
polymers was noted. As shown in Figure 7A, at low grafting concentrations (≤ 2 mM) small 
molecular weight mPEG demonstrated superiority over large polymers when modifying the 
virus (RSV) directly. At these low virus:mPEG ratios the improved efficacy of the 2 kDa 
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polymer may be partially due to the distribution of virus specific proteins within the viral 
envelope. On the RSV virion the G (attachment) and F (fusion) proteins form glycoprotein 
spikes that are 6-10 nm apart and extent 11-20 nm from the virion surface. Thus, given the 
distance between glycoprotein spikes on the RSV virion, grafting of 2 kDa mPEG will likely 
result in the direct modification of a greater number of glycoprotein spikes. Grafting of 20 
kDa mPEG will likely result in fewer spikes being modified as the initially bound mPEG 
will exclude other polymer chains from grafting to spikes in close proximity. At higher 
grafting concentrations, the self-exclusion effect of grafted mPEG is partially overcome 
resulting in high levels of surface modification and prevention of viral binding to the host 
cell. Importantly, soluble mPEG (i.e., unable to covalently modify the virus) had no antiviral 
effect. In support of these observations, our previous studies clearly demonstrated that 
binding of mPEG-modified RSV or SV40 to the target cells is dramatically decreased as 
determined by immunofluorescence staining 90 minutes post challenge at 4°C (to prevent 
internalization).[McCoy and Scott, 2005; Sutton and Scott, 2010]  
While the utility of direct viral modification might be beneficial in blood banking 
environments bereft of modern viral detection methodology, this application would have 
little or no practical value in the prevention of respiratory disease. To this end, the in vitro 
PEGylation of the host cell monolayers were conducted. These studies have demonstrated 
that the selection of the polymer molecular weight and grafting concentration are important 
in preventing viral infection. 
In contrast to Figure 7A, small chain polymers were completely ineffective when used to 
directly modify the RSV host cell – even at very high grafting concentrations (Figure 7B). 
This suggests that the unknown membrane receptor for RSV extends well away from the 
membrane surface and the 2 kDa polymer is unable to effectively camouflage it. However, 
cellular grafting of small polymers may provide partial protection against some viruses. As 
shown in Figure 8, low molecular weight mPEG (3.4 kDa) when grafted to host cells does 
provide anti-viral protection over multiple logs of viral challenge when using SV40. Even at 
very high levels SV40 challenge (e.g., 1011 pfu/ml) grafted polymer (20 > 3.4 kDa) offered 
very significant protection against infection and viral proliferation as evidenced by the 
significant decrease in infected cells. For example, unmodified host cells infected with 107 
pfu/mL were 27% infected, while those modified by 1.2 and 15 mM 3.4 kDa mPEG were 6% 
and 0.6% infected. In contrast, the 20 kDa polymer at the 1.2 and 15 mM grafting 
concentrations when challenged with 107 pfu/mL resulted in infection rates of only 2% and 
0.05%, respectively. In contrast to RSV, the viral receptor for SV40 is known to be MHC-1, a 
molecule that extends approximately 7 nm from the cell membrane. The protection offered 
by the small polymer is inferior to that offered by the 20 kDa mPEG but is still significant 
relative to unmodified cells. As with RSV, and in all models tested, soluble mPEG (i.e., 
unable to covalently modify the host cell surface) had no antiviral effect. 
The observed relationship between polymer molecular weight and the physical size of the 
grafting target was consistently observed across multiple viral models. Further analysis of 
the relationship was examined using a latex bead – plasma adsorption model to which 
mPEGs of various molecular weights were grafted (Figure 9). Using small latex beads (1.2 
µm), short chain polymers were more effective as noted by the decreased amount of 
adsorbed fluorescently labeled plasma protein. In contrast, with large 8 µm latex beads (or 
8µm RBC) large chain polymers are most effective at preventing the adsorption of the 
fluorescently labeled plasma. In agreement with this finding, PEGylation of viruses (0.02-200 
µm) also demonstrate that short chain polymers (2 kDa) are more effective at preventing 
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viral invasion and infection while large chain polymers provide superior protection when 
grafted to host cells (e.g., RSV; Figure 7). 
 
 
Fig. 7. PEGylation of virus (A) or host cell (B) can prevent viral invasion and proliferation. 
Shaded areas denote normal range of infection for control studies. An MOI of 0.01 was used 
for both panels. Shown are the mean ± SD of a minimum of 3 independent experiments. 
Data modified from: [Sutton & Scott, 2010] 
 
 
Fig. 8. In contrast to RSV, infection by other viruses is partially blocked by the grafting of 
short chain polymers to the host cells. CV-1 cells were modified with the indicated 
concentrations of activated mPEGs of 3.4 (A) or 20 (B) kDa and challenged over a broad 
range of viral titers. Percent infected cells was determined at 72 hours via T antigen staining. 
The mean ± standard deviation of 3 independent experiments are shown. Data modified 
from: [McCoy & Scott, 2005] 
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Fig. 9. Paradoxically, the size of the PEGylation target influences which polymer size most 
effectively imparts immunocamouflage. Modified from Le and Scott (2010). [Le & Scott, 
2010] 
To determine if a nasal gel would adequately cover the tissue of interest, in vivo studies were 
conducted. To assess the area of coverage, a polymer gel formulation was labeled with India 
Ink and administered intranasally (150µl per nostril) in a Guinea Pig model of Respiratory 
Syncytial Virus (RSV) infection. These studies demonstrated full coverage of the nasal cavity 
and even significant protection to the level of the lung (Figure 10).  
Indeed, studies using a pigmented nasal gel demonstrated that a gel can provide protection 
to both the upper and lower respiratory tract in a Guinea Pig model of respiratory Syncytial 
Virus (RSV). Dissection of the Guinea Pig nasal cavity demonstrated uniform staining of the 
cavity surface. Moreover, as shown in Figure 10, application of a PEG-based gel containing 
India Ink resulted in significant protection even within the lung tissue. 
To date, we have demonstrated that the covalent grafting of mPEG to virus itself or to the 
host/target cell results in a highly effective broad-spectrum antiviral prophylaxis. 
Consequent to the immunocamouflage of the host cell, viral entry and propagation by 
members the Picornaviridae, Adenoviridae, Cornaviradae, Pneumovirus (all representative of 
common human respiratory viruses) families as well as members of the Papovaviridae and 
Hepesviridae families are virtually (≥90%) blocked even at high viral titers. Furthermore, this 
antiviral prophylaxis is effective against: 1) enveloped and non-enveloped viruses; 2) 
receptor-mediated and fusiogenic viruses; 3) small and large viruses; 4) DNA and RNA 
viruses; and 5) viruses with known and unknown viral receptors. The mechanism of this 
protection is biophysical (not immunological) in nature and dependent upon charge 
camouflage and steric hindrance induced by the grafted polymer. Importantly, due to the 
basic biophysical nature of this antiviral effect, it is not prone to biological adaptation (i.e., 
sequence mutations obviating the efficacy of antibodies) by the virus. 
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Fig. 10. Penetration of the nasal gel within the nasal cavity (A) and to the lower respiratory 
tract (B) was examined within a Guinea Pig model of Respiratory Syncytial Virus (RSV) 
infection. Shown are the nasal cavity and whole lung and sagittal sections of the lung lobes 
one hour after intranasal administration of 300 µl (150 per nostril) of India ink labelled 
polymer gel. The non-sinus tissues is partially masked. Note the distribution of the ink, 
indicative of the successful delivery of the nasal polymer to the nasal cavity and regions of 
the lung. 
3.2 Alternative preventative or therapeutics approaches 
Current methods to prevent respiratory viral disease range from homeopathic drug 
treatments (e.g., mega doses of vitamin C, oral zinc and Echinacea) to pharmacological 
interventions such as anti-viral drugs and vaccination. Many of these methods have been 
proven ineffective (vitamin C) or are not always practical or effective (i.e., mass vaccination) 
in preventing disease. [Block & Mead, 2003, Yale & Liu, 2004]  
Potential pharmacological means of preventing viral infections are to block either viral 
entry, or proliferation, within the host cell. However again there are no United States FDA-
approved broad spectrum prophylactic therapies or anti-viral treatments capable of 
preventing either of these events. Most approved pharmacological antiviral agents exhibit 
high specificity. Among the best described prescription antiviral agent is Amantadine (FDA 
approved in 1966), which is used to prevent the uncoating of influenza A. Within cells, 
Amantadine specifically inhibits viral uncoating by blocking the activity of the proton 
channel of the influenza A M2 protein preventing the endosomal pH change required for 
uncoating to occur. [Kandel & Hartshorn, 2001] However, Amantadine has only a brief 
window of efficacy and is highly specific to influenza A (i.e., completely ineffective against 
other influenza strains much less different viral families). Most recently the U.S. Center for 
Disease Control (CDC) recommends against the use of Amantadine due to viral resistance. 
In its place, the CDC has recommended the use of Tamiflu® (Oseltamivir; FDA approved 
1999) to prevent or treat influenza A and B infections. Oseltanmivir is a neuraminidase 
inhibitor that is specific to influenza and blocks the exit of the progeny influenza viruses 
from the host cell, thus limiting viral replication and disease progression. However, the 
efficacy of Tamiflu® has recently been reassessed ([Jefferson et al., 2009]) and found to offer 
only modest prophylaxis when administered within 24 hours of viral infection. Other 
prescription antiviral drugs demonstrate similar limited or absent efficacy against other 
respiratory viral families (Rhinoviruses, Coronaviruses, and Adenoviruses) associated with 
cold or flu causation.  
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Thus, patients typically turn to over-the-counter (OTC) cough and cold remedies which 
focus on the relief of symptoms associated with the common cold. Currently in North 
America alone an estimated $3-6 billion (US) is spent on symptom relief. A few OTC 
compounds do attempt to prevent or, after infection, attenuate viral infection. These 
commercial products include compounds such as ZICAM Nasal Gel (active ingredient: zinc 
gluconate) and ColdFX (active ingredient: proprietary natural extract containing poly-
furanosyl-pyranosyl-saccharides in a concentration of greater than 80%). [Hirt et al., 2000, 
McElhaney et al., 2006] For drug efficacy, ZICAM must be applied intranasally every 2-4 
hours. However, Zicam’s proven mode of action is highly specific and, in laboratory studies, 
only prevents infection by those rhinoviruses that use ICAM1 as the viral receptor. [Bella & 
Rossmann, 1999] Hence, it is completely ineffective against the majority of cold viruses that 
do not use ICAM1 (e.g., Coronaviruses and Adenoviruses). More recently, in 2009 ZICAM’s 
original intranasal formulation was removed from the market due to adverse side effects. 
[Lim et al., 2009] ColdFX’s mode of action and viral range of efficacy are not as well 
documented, though clinical studies do suggest variable degrees of efficacy in small 
population studies. Studies cited by ColdFX suggest that the natural ingredients stimulate 
the immune system (e.g., activate macrophages, increase natural killer (NK) cell numbers) to 
both prevent initial viral infection and to more efficiently kill off virally infected cells to 
prevent viral proliferation. [Wang et al., 2004, Miller et al., 2009] However, direct 
experimental evidence for these purported actions is limited. 
Other experimental approaches have also been investigated but are also are highly specific 
to single viral strains and/or families. For example, two other experimental methods of 
preventing rhinoviral infection have been studied which, like ZICAM, targets the 
rhinovirus:ICAM-1 interaction. These are the intranasal application of soluble Intracellular 
Adhesion Molecule (sICAM) or anti-ICAM-1 antibodies (rhinovirus receptor murine 
monoclonal antibody; RRMA). Like ZICAM, these experimental drugs require intranasal 
application every 2-4 hours. [Marlin et al., 1990, Huguenel et al., 1997, Turner et al., 1999] 
Both of these drugs do demonstrate some in vitro and in vivo (murine) efficacy against 
rhinoviruses. Randomized human trials with sICAM demonstrated that intranasal 
administration of sICAM 7 hours prior to or 12 hour post rhinovirus challenge resulted in a 
relative reduction in cold symptoms but very weak prevention (92% of the placebo-treated 
subjects and 85% of the sICAM-treated subjects became infected). [Turner et al., 1999] 
Similarly, human trials with RRMA demonstrated no reduction in rhinovirus infection or 
disease severity. [Hayden et al., 1988, Sperber & Hayden, 1989] Furthermore, repeated 
administration of the mouse derived RRMA would also lead to rapid immunization against 
the drug. Importantly, unlike the described mPEG nasal gel, both sICAM and RRMA are 
highly specific to only those Rhinoviruses that utilize ICAM-1 as the viral receptor. For 
example, when sICAM was tested against herpes simplex virus type 1 (HSV-1), coxsackie 
virus B1 or poliovirus no observable protective effect was noted. [Marlin et al., 1990]  
Thus, the antiviral prophylactic polymer nasal gel illustrated here represents the only broad 
spectrum antiviral prophylactic agent described to date. Application of the activated nasal 
gel is uncomplicated and requires a minimal (~3-5 minutes) application time to effectively 
camouflages known and unknown viral receptors. After application, the individual then 
simply “blows their nose” into a tissue to remove any residual carrier fluid. Current data 
suggests that a single daily application provides maximal protection and retains significant 
efficacy for up to 60 hours. A brief comparison of a cross sample of the above approaches 
with our proposed antiviral nasal gel is shown in Table 2A/B. 
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A. Anti-Viral Activity Against Respiratory Viruses 
Viral Family 
mPEG 
Nasal 
Gel 
RRMAa 
Soluble 
ICAM 
Zicam 
Traditional 
Vaccination 
Adenoviridae + - - - +/- 
Coronaviridae + - - - +/- 
Herpesviridae + - - - +/- 
Papovaviridae + - - - +/- 
Picornaviridae + +*/- +*/- +*/- - 
Retoviridae + - - - +/- 
Paramyxoviridae + - - - +/- 
      
B. Phamacological Traits 
 Gel RRMAa 
Soluble 
ICAM 
Zicam 
Traditional 
Vaccination 
Non-Specific 
Protection 
Yes No No No No 
Non-Immunogenic Yes ? ? + +/- 
Lack of Inherent 
Resistance 
Yes ? ? +/- +/- 
Longevity of 
Protection by a Single 
Application 
24-48 Hr 2-4 Hr* 2-4 Hr* 2-4 Hr* ** 
a Anti-ICAM Antibody; +/- Highly Strain Specific; * Only against Rhinoviruses utilizing ICAM-1 as 
viral receptor; ** Protection if generated, can last weeks to years. 
Table 2. Comparison of the antiviral (A) and pharmacological (B) traits of the described 
mPEG-Nasal Gel to other experimental and commercial antiviral agents. 
3.3 Non-respiratory antiviral applications 
Are there other applications for an antiviral prophylactic gel? Humans are beset by a host of 
viral pathogens and common to all of these pathogens is the need to gain entry into its target 
cell in order to proliferate. Not all viruses or modes of entry (e.g., i.v. drug use) would be 
amendable to an antiviral gel. However, the use of an antiviral gel in preventing or reducing 
the risk of an initial infection by the Human Immunodeficiency Virus (HIV) could be 
envisioned. [Piguet & Steinman, 2007, Cutler & Justman, 2008, Boily et al., 2009, Garg et al., 
2010]  
In both male-female and male-male transmission, the HIV virus typically enters the host via 
Langerhans cells, a resident epidermal dendritic cell, dermal dendritic cells, and/or resident 
CD4+ lymphocytes all of which are present within the mucosal and sub-epithelial tissues of 
the anogenital region (Figure 11A). Viral entry is gained primarily via two receptors located 
on the surface of the cell: CD195 (CCR5) and CD184 (CXCR4). [Piguet & Steinman, 2007] If 
dendritic (antigen presenting) cells capture the virus, it is either endocytosed or can be 
transferred directly to CD4+ CD195+ T lymphocyte via an infection synapse. Proliferation of 
the virus within T cells is followed by infection of additional lymphocytes via either CD184 
or CD195. Importantly, all of these events are analogous to cellular invasion by respiratory 
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viruses and amendable to disruption by grafted polymer. In a model analogous to 
spermicide or lubricant, an activated polymer gel could be applied either vaginally or anally 
prior to at-risk behavior creating an antiviral barrier on the epithelial cell surfaces of the 
mucosal tissue (Figure 11B) and preventing viral binding via the biophysical mechanisms 
already described. As shown in Figure 12, proof-of-concept studies clearly demonstrate that 
grafting of mPEG to CD184 and CD195 positive cells inhibits recognition of these markers 
by high affinity antibodies. 
 
 
Fig. 11. Immunocamouflage of HIV receptors by activated mPEG antiviral gel. Panel A) 
Normal mode of HIV invasion; Panel B) Blockade of HIV binding by activated mPEG gel. 
Langerhan Dendritic Cells (LC); Dermal Dendritic Cells (DC); CD4+ T Lymphocyte (T-Cell). 
Langerin, a lectin present on LCs is a primary attachment point for HIV. A different lectin 
(DC-SIGN) is present on other DC and serves as a receptor for HIV. Noncellular entry may 
occur via epithelial cell injury (e.g., microabrasions). 
Because the risk of HIV transmission per single interaction is relatively low (estimated to be 
0.04% for female-to-male; 0.08% for male-to-female; and 1.7% for receptive anal intercourse; 
Boily et al., 2009), the application of an effective activated mPEG-based mucosally applied 
antiviral gel would further reduce the risk of transmission. Moreover, PEG itself is a 
lubricant and would reduce the risk of traumatic tissue injury and microabrasions – known 
risk factors in HIV transmission. The lubricant effect of the mPEG-gel would be of particular 
importance with regards to anal transmission as the anal epithelium ranges from a multi- to 
single-layer epithelial lining prone to tearing (in contrast to the vagina which is a 
multicellular stratified squamous epithelium and resistant to traumatic injury). This simple 
anatomical difference in large part underlies the differential transmission risk associated 
with anal intercourse. Finally, the immunocamouflage of the infected dendritic cells and 
macrophages would also make the cells less prone to activation by other pathogens due to 
the camouflage of key surface receptors. In the absence of activation, HIV proliferation 
within infected cells is greatly diminished decreasing viral shedding. 
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Fig. 12. Immunocamouflage of HIV receptors by activated mPEG antiviral gel. As shown, 
PEGylation of dendritic cells and lymphocytes results in the immunocamoufalge of CD184 
and CD195 as detected by high affinity monoclonal antibodies to the CD determinants. The 
efficacy of the immunocamouflage is concentration dependent. 
Indeed, there are several topical microbiocidal gels in clinical trials that aim to prevent 
against HIV infection either non-specifically (surfactants and acidifying agents) or 
specifically (viral entry and reverse transcriptase inhibitors). Some surfactants, such as 
nonoxynol-9, experimentally were shown to result in viral disruption but also exerted 
toxicity to host cells. Further clinical trials of nonoxynol-9 in HIV endemic areas actually 
demonstrated increased risk of HIV infection with its use. [Rustomjee et al., 1999, Van 
Damme et al., 2002, Herold et al., 2011] These studies suggested that the surfactant-induced 
mucosal injury appeared to mimic the presence of microabrasions already known to 
increase HIV transmission. Other surfactants such as sodium lauryl sulfate (invisible 
condom) disrupt enveloped and non-enveloped viruses and are associated with decreased 
(relative to nonoxynol-9) mucosal toxicity. [Howett & Kuhl, 2005, Mbopi-Keou et al., 2010] In 
contrast to surfactants, the mPEG antiviral gel is of low toxicity to cells while 
simultaneously providing significant camouflage of the mucosal surface thereby preventing 
or decreasing the initial viral interaction with resident dendritic cells and T lymphocytes.  
4. Conclusion 
The safe, low cost, low technology, non-toxic, and transient bioengineering of the terminally 
differentiated nasal pharyngeal epithelial host cells may provide a radically new antiviral 
prophylactic approach. Moreover, this approach may be applicable to other non-respiratory 
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viruses in which a polymer gel can be applied. This antiviral protection arises from the 
ability of the grafted polymer to directly impede cellular invasion and subsequent 
proliferation thus abrogating the disease process at its initial stage. Moreover, this 
technology is effective against: 1) enveloped and non-enveloped viruses; 2) receptor-
mediated and fusiogenic viruses; 3) small and large viruses; 4) DNA and RNA viruses; and 
5) viruses with known and unknown viral receptors.  
The envisioned use of this prophylactic technology is via a simple intranasal gel application 
in at risk individuals in acute, high transmissibility, environments (e.g., nosocomial spread, 
refugee centers, bioterrorism, airplanes, or with visiting grandchildren). For example, within 
refugee centers, epidemiological analyses demonstrate that, alongside malnutrition and 
diarrhea, acute respiratory infections are a major cause of morbidity and mortality (e.g., 
Figure 6). Under identical circumstances, traditional vaccines, even if they were available, 
would not be able to prevent widespread dissemination of disease while this novel 
intranasal anti-viral prophylactic provides immediate, albeit transient, protection against a 
broad spectrum of respiratory viral pathogens. 
Application of the activated nasal gel is surprisingly uncomplicated and requires a minimal 
(~3-5 minutes) application time to the host (e.g., nasopharyngeal) cells but effectively 
camouflages known and unknown viral receptors thus protecting against a broad spectrum 
of viral pathogens. Of note, nasal epithelial cells are terminally differentiated and slough off 
after about 4 days and are biologically outside the body resulting in minimal systemic 
exposure to the mPEG polymer. The polymer itself has an extremely safe toxicity profile and 
is commonly used in current pharmaceuticals (most often as a stabilizer or binding agent), 
cosmetics and food preparations. After application, the individual then simply “blows their 
nose” into a tissue to remove any residual carrier fluid. Furthermore, preliminary data 
suggests that a single daily application provides maximal protection and even retains 
significant efficacy for up to 60 hours.  
Respiratory pathogens can, and do, create massive healthcare emergencies in at risk 
populations. The development of this inexpensive, easy to use intranasal antiviral gel would 
be of significant health and economic benefit to both the at risk individual and to 
governmental and health agencies addressing respiratory disease crises. Importantly, the 
term ‘at risk’ is relative and may range from environmental or political upheavals to more 
mundane environments such as air travel and visiting grandchildren. 
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